These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31378916)

  • 1. A prospective study of the effects of carbocysteine lysine salt on frequency of exacerbations in COPD patients treated with or without inhaled steroids.
    Paone G; Lanata L; Saibene F; Toti S; Palermo P; Graziani C; Flore MC; Ramaccia M; Puglisi G
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6727-6735. PubMed ID: 31378916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
    Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
    Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of mucolytics in COPD: A Delphi consensus study.
    Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
    Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
    Yang IA; Fong KM; Sim EH; Black PN; Lasserson TJ
    Cochrane Database Syst Rev; 2007 Apr; (2):CD002991. PubMed ID: 17443520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
    Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
    COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys).
    Carpagnano GE; Resta O; Foschino-Barbaro MP; Spanevello A; Stefano A; Di Gioia G; Serviddio G; Gramiccioni E
    Eur J Pharmacol; 2004 Nov; 505(1-3):169-75. PubMed ID: 15556150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
    Magnussen H; Disse B; Rodriguez-Roisin R; Kirsten A; Watz H; Tetzlaff K; Towse L; Finnigan H; Dahl R; Decramer M; Chanez P; Wouters EF; Calverley PM;
    N Engl J Med; 2014 Oct; 371(14):1285-94. PubMed ID: 25196117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of inhaled bronchodilator therapy in patients hospitalized for non-life-threatening COPD exacerbations.
    Woods JA; Usery JB; Self TH; Finch CK
    South Med J; 2011 Nov; 104(11):742-5. PubMed ID: 22024782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
    Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.
    Papi A; Zheng J; Criner GJ; Fabbri LM; Calverley PMA
    Respir Med; 2019 Feb; 147():37-43. PubMed ID: 30704697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
    Welsh EJ; Cates CJ; Poole P
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD007891. PubMed ID: 23728670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.
    Magnussen H; Watz H; Kirsten A; Decramer M; Dahl R; Calverley PM; Towse L; Finnigan H; Tetzlaff K; Disse B
    Respir Med; 2014 Apr; 108(4):593-9. PubMed ID: 24477080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: results of the detection, intervention, and monitoring of COPD and asthma program.
    Albers M; Schermer T; van den Boom G; Akkermans R; van Schayck C; van Herwaarden C; van Weel C
    Chest; 2004 Dec; 126(6):1815-24. PubMed ID: 15596679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.